BioSpace News Archive

ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA ®

ProMIS Neurosciences, Inc. announced today its participation in H.C. Wainwright & Co., 23rd Annual Investment Conference being held virtually September 13-15 2021.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has completed the funding of the Study Protocol phase of its recently initiated Clinical Trial.

Digital health refers to the utilization of electronic communication or information technology-based processes, tools, and services to facilitate better healthcare services.

Polyclonal antibodies are potentially powerful tools in a wide range of biomedical and biochemical research, world over.

TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others.

Providence Therapeutics Holdings Inc. announced two separate definitive agreements with Everest Medicines Limited, to license rights to Providence’s mRNA COVID-19 vaccine candidates in emerging markets in Asia, including Greater China, Southeast Asia and Pakistan, and establish a broad, strategic partnership to develop mRNA products globally leveraging Providence’s cutting-edge mRNA technology platform.

Amarin Corporation plc announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021.

VistaGen Therapeutics, Inc. announced the initiation of PALISADE-2, the second U.S. Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of PH94B for the acute treatment of anxiety in adults with social anxiety disorder.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap’s anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab,